drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Antibody–drug conjugate linking trastuzumab to the cytotoxic microtubule inhibitor DM1 to deliver targeted chemotherapy to HER2-overexpressing tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Ado-Trastuzumab Emtansine
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Trastuzumab (anti-HER2 IgG1) is conjugated to the maytansinoid DM1. The antibody binds HER2 on tumor cells and is internalized; lysosomal processing releases DM1, which inhibits microtubule assembly, causing mitotic arrest and apoptosis. The trastuzumab moiety also blocks HER2 signaling and can mediate ADCC.
drug_name
Ado-trastuzumab emtansine (T-DM1)
nct_id_drug_ref
NCT05705401